Neta Goldschmidt
Overview
Explore the profile of Neta Goldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, et al.
Am J Hematol
. 2022 Nov;
98(2):E24-E27.
PMID: 36349541
No abstract available.
12.
Lebel E, Goldschmidt N, Siegal T, Lossos A, Rosenberg S, Makranz C, et al.
Leuk Lymphoma
. 2022 May;
63(9):2102-2108.
PMID: 35491706
The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown. We report our experience with rituximab, HDMTX, procarbazine and lomustine (R-MPL) given as first-line treatment...
13.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz O, et al.
Ann Hematol
. 2022 Jan;
101(4):755-762.
PMID: 35083525
Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing...
14.
Morgenstern Y, Aumann S, Goldschmidt N, Gatt M, Nachmias B, Horowitz N
Cancer Med
. 2021 Nov;
10(24):8866-8875.
PMID: 34816617
Purpose: Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose-adjusted (DA)...
15.
Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, et al.
Haematologica
. 2021 Jul;
107(3):625-634.
PMID: 34320789
Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced....
16.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson N, et al.
Lancet Oncol
. 2021 Mar;
22(4):512-524.
PMID: 33721562
Background: PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study...
17.
Gazal S, Lebel E, Kalish Y, Makranz C, Gatt M, Goldschmidt N, et al.
Oncol Res Treat
. 2020 Dec;
44(1-2):52-57.
PMID: 33296909
Background: Venous thromboembolism (VTE) is a frequent, potentially lethal complication in individuals with cancer. Patients with brain tumors are at particularly high risk for VTE. Primary central nervous system lymphoma...
18.
Mei-Zahav M, Gendler Y, Bruckheimer E, Prais D, Birk E, Watad M, et al.
J Clin Med
. 2020 Oct;
9(10).
PMID: 32998220
Epistaxis is a common debilitating manifestation in hereditary hemorrhagic telangiectasia (HHT), due to mucocutaneous telangiectases. The epistaxis can be difficult to control despite available treatments. Dysregulated angiogenesis has been shown...
19.
Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, et al.
Leuk Lymphoma
. 2020 Sep;
62(1):118-124.
PMID: 32981410
The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real...
20.
Paltiel O, Raviv Sharabi G, Tzemach R, Rechavi T, Trachtenberg E, Goldschmidt N, et al.
BMJ Qual Saf
. 2020 May;
30(4):300-310.
PMID: 32467340
Background: Under the 'Choosing Wisely' (CW) framework, professional organisations internationally have advocated limiting imaging for asymptomatic patients following curative cancer therapy, based on limited value and high cost. F18-fluorodeoxyglucose (FDG)...